MedPath

Research Initiative Launches to Address Mental Health Crisis in Rare Disease Diagnoses

  • RBW Consulting partners with Rare Disease Research Partners to investigate the psychological impact of rare disease diagnoses, affecting 3.5-5.9% of the global population.

  • The research project, led by Dr. Tom Kenny, aims to develop comprehensive guidelines for healthcare professionals to better support patients and families during diagnosis.

  • Study findings and industry guidelines are expected to be published by winter 2021, addressing the critical gap in mental health support frameworks for rare disease patients.

The intersection of rare diseases and mental health is gaining critical attention as RBW Consulting launches a groundbreaking research initiative to examine the psychological impact of rare disease diagnoses. This effort addresses a significant healthcare gap affecting between 3.5% and 5.9% of the world's population living with rare conditions.

Understanding the Rare Disease Landscape

Rare diseases, predominantly genetic in origin (72%), present unique challenges in diagnosis and treatment. These conditions often manifest in young children and are typically chronic and life-threatening. The path to diagnosis is frequently complicated by common symptoms masking underlying rare conditions, leading to delays in proper treatment and significant impact on patient autonomy.

Mental Health Burden of Diagnosis

The moment of diagnosis represents a critical juncture in a patient's journey, with far-reaching implications for both patients and their families. Emma Thorp, Chief Growth Officer at RBW Consulting, shares her personal experience with her mother's diagnosis of Primary CNS lymphoma, highlighting the overwhelming focus on physical treatment while mental health support remained notably absent.
"The pressure that a rare disease diagnosis places on patients and families is immeasurable – both mentally and physically, but the framework to cope with this strain isn't out there," Thorp emphasizes.

Research Initiative Details

Dr. Tom Kenny, CEO of Rare Disease Research Partners, is spearheading the research effort. The project commenced in January 2021 with a comprehensive literature review, followed by the appointment of an expert advisory group including psychologists and family representatives in March 2021.
"My goal for this research is to draw together the existing evidence in a way that can be used by healthcare professionals to support patients, their families and caregivers at this critical moment," explains Dr. Kenny. The initiative aims to create a consolidated collection of current evidence and best practices while identifying crucial knowledge gaps requiring further investigation.

Addressing Healthcare Disparities

The research acknowledges the broader social and financial challenges faced by rare disease patients. Current healthcare systems often create inequalities in access to appropriate care, amplifying the burden on patients and their families. The project seeks to develop a structured mental health framework specifically tailored to rare disease diagnosis scenarios.

Future Impact and Deliverables

The initiative will culminate in the publication of research findings and industry guidelines by winter 2021. This milestone represents the beginning of a broader dialogue aimed at establishing comprehensive mental health support systems for the rare disease community. The project's outcomes are expected to provide healthcare professionals with practical tools to better support patients and families during the crucial diagnosis phase.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

© Copyright 2025. All Rights Reserved by MedPath